WALDO
Website unreachable since Oct 28, 2026
The startup offers contact lenses designed with enhanced moisture retention, UV protection, and high oxygen permeability to improve comfort for users. By utilizing a direct-to-consumer subscription model, the company provides affordable access to these advanced lenses, addressing the common issue of dry eyes associated with traditional contact lens wear.
- Commerce & Shopping
- Consumer Goods
- Healthcare Technology
Funding
Raised to date
$15.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many contact lens wearers experience discomfort, including dry eyes, due to inadequate moisture retention and oxygen permeability in traditional lenses. High costs and inconvenient purchasing processes further exacerbate these issues.
Solution
WALDO offers daily contact lenses designed to enhance comfort and ocular health through improved hydration and oxygen transmissibility. These lenses incorporate Vitamin B12 to provide 30% more hydration and twice the comfort compared to standard lenses. By utilizing a direct-to-consumer subscription model, WALDO provides affordable access to high-quality lenses, delivered directly to the customer's door with free shipping after the initial trial. The subscription is flexible, allowing users to easily modify, pause, or cancel their plan as needed.
Target Audience
WALDO's primary customers are individuals who wear contact lenses daily and seek a comfortable, convenient, and affordable solution with a flexible subscription model.
Features
- Daily disposable lenses for optimal hygiene and convenience
- Vitamin B12-infused lenses for enhanced hydration and comfort
- High water content and oxygen transmissibility for all-day wear
- Direct-to-consumer subscription model for cost savings
- Flexible subscription management with easy modification, pausing, or cancellation options
- Free shipping on all orders following the initial trial